What is Sciwind Biosciences?
Headquartered in Hangzhou, China, Sciwind Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics. The company's strategic positioning within the competitive biopharma landscape is bolstered by substantial financial backing, enabling it to advance its research and development initiatives. This investment is crucial for navigating the complex and capital-intensive process of drug discovery and clinical trials, aiming to bring novel treatments to market.
How much funding has Sciwind Biosciences raised?
Sciwind Biosciences has raised a total of $70M across 1 funding round:
Series C
$70M
Series C (2021): $70M with participation from LYFE Capital, IDG Capital Partners, and Loyal Valley Capital
Key Investors in Sciwind Biosciences
LYFE Capital
LYFE Capital is a healthcare investment platform focused on critical supply chain assets, specialized product platforms, and next-generation R&D services, aiming to scale high-potential businesses in the healthcare sector.
IDG Capital Partners
IDG Capital is an investment firm focused on developing companies through private equity, venture capital, and mergers and acquisitions, with a presence in China and Boston.
Loyal Valley Capital
Loyal Valley Capital is a thematic, research-oriented private equity firm that partners with promising companies, having been involved in the funding of prominent players in various sectors.
What's next for Sciwind Biosciences?
With the recent major strategic investment, Sciwind Biosciences is poised for accelerated expansion and advancement of its drug development programs. The substantial capital infusion is expected to fuel further clinical trials, enhance research capabilities, and potentially broaden the company's therapeutic focus. This funding round signifies a critical juncture for Sciwind Biosciences, positioning it to achieve key milestones and solidify its presence in the global biopharmaceutical market. The company's trajectory suggests a focus on scaling operations and progressing its pipeline through later-stage development.
See full Sciwind Biosciences company page
